Swapna Mandal

Dr. Swapna Mandal

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Open access
RPRicardo Polman
Ricardo Polman
JHJohn Hurst
John Hurst
OUOmer Faruk Uysal
Omer Faruk Uysal
SMSwapna Mandal
Swapna Mandal
Dominik LinzDominik Linz
Dominik Linz
SSSami Simons
Sami Simons
1. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as ‘a heterogeneous lung condition, characterized by chronic respiratory symptoms (dyspnoea, cough, expectoration a...

27 November 2023 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
ASAmar J. Shah
Amar J. Shah
MAMalik A. Althobiani
Malik A. Althobiani
ASAnita Saigal
Anita Saigal
COChibueze E. Ogbonnaya
Chibueze E. Ogbonnaya
JHJohn R. Hurst
John R. Hurst
SMSwapna Mandal
Swapna Mandal
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death and is associated with multiple medical and psychological comorbidities. Therefore, future strategies to improve COPD management and outcomes are needed for the betterment of patient care. Wearable technology interventions offer considerable promise in improving outcomes, but prior reviews fall short of assessing their role in the COPD population. In this systematic review and meta-analysis we searched ovid-MEDLINE, ovid-EMBASE, CINAHL, CENTRAL, and IEEE databases from inception to April 2023 to identify studies investigating wearable technology interventions in an adult COPD population with prespecified outcomes of interest including physical activity promotion, increasing exercise capacity, exacerbation detection, and quality-of-life. We identified 7396 studies, of which 37 were included in our review. Meta-analysis showed wearable technology interventions significantly increased: the mean daily step count (mean difference (MD) 850 (494–1205) steps/day) and the six-minute walk distance (MD 5.81 m (1.02–10.61 m). However, the impact was short-lived. Furthermore, wearable technology coupled with another facet (such as health coaching or pulmonary rehabilitation) had a greater impact that wearable technology alone. Wearable technology had little impact on quality-of-life measures and had mixed results for exacerbation avoidance and prediction. It is clear that wearable technology interventions may have the potential to form a core part of future COPD management plans, but further work is required to translate this into meaningful clinical benefit.

13 November 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
AAAhmed Alrajeh
Ahmed Alrajeh
YAYousef S Aldabayan
Yousef S Aldabayan
AAAbdulelah Mastour Aldhahir
Abdulelah Mastour Aldhahir
EPElisha Pickett
Elisha Pickett
SQShumonta Quaderi
Shumonta Quaderi
JHJohn Hurst
John Hurst
Background: Earlier detection of chronic obstructive pulmonary disease (COPD) exacerbations may facilitate more rapid treatment with reduced risk of hospitalization. Changes in pulse oximetry may permit early detection of exacerbations. We hypothesized that overnight pulse oximetry would be superior to once-daily monitoring for the early detection of exacerbations. Objective: This study aims to evaluate whether measuring changes in heart rate and oxygen saturation overnight is superior to once-daily monitoring of both parameters and to assess symptom changes in facilitating earlier detection of COPD exacerbations. Methods: A total of 83 patients with COPD were randomized to once-daily or overnight pulse oximetry. Both groups completed the COPD assessment test questionnaire daily. The baseline mean and SD for each pulse oximetry variable were calculated from 14 days of stable monitoring. Changes in exacerbation were expressed as Z scores from this baseline. Results: The mean age of the patients was 70.6 (SD 8.1) years, 52% (43/83) were female, and the mean FEV1 was 53.0% (SD 18.5%) predicted. Of the 83 patients, 27 experienced an exacerbation. Symptoms were significantly elevated above baseline from 5 days before to 12 days after treatment initiation. Day-to-day variation in pulse oximetry during the stable state was significantly less in the overnight group than in the once-daily group. There were greater relative changes at exacerbation in heart rate than oxygen saturation. An overnight composite score of change in heart rate and oxygen saturation changed significantly from 7 days before initiation of treatment for exacerbation and had a positive predictive value for exacerbation of 91.2%. However, this was not statistically better than examining changes in symptoms alone. Conclusions: Overnight pulse oximetry permits earlier detection of COPD exacerbations compared with once-daily monitoring. Monitoring physiological variables was not superior to monitoring symptoms, and the latter would be a simpler approach, except where there is a need for objective verification of exacerbations. Trial Registration: ClinicalTrials.gov NCT03003702; https://clinicaltrials.gov/ct2/show/NCT03003702

24 July 2022 in Lung
Verified
Journal Article
Open access
PDF file
ASAmar J. Shah
Amar J. Shah
KFKatia Florman
Katia Florman
NKNitika Kaushal
Nitika Kaushal
HKHiu Fung Kwong
Hiu Fung Kwong
AKAkul Karoshi
Akul Karoshi
SMSwapna Mandal
Swapna Mandal
Few international studies have investigated factors affecting domiciliary non-invasive ventilation (D-NIV) compliance, and data from the UK are limited. We assessed compliance (defined as ≥ 4 h/night for at least 70% of the time) in a retrospective UK population study, at three time points (0–1 month, 3–4 months and 11–12 months), for all patients commenced on D-NIV over a 5-year period. A total of 359 patients were included. Non-compliant vs. compliant patients were significantly younger (median age 64 (IQR 52–72) vs. 67 (58–75) years, p = 0.032) and more likely to have schizophrenia, consistent at both 3–4 months (5% vs. 1%, p = 0.033) and 11–12 months (5% vs. 2%, p = 0.049). Repeated measures ANOVA demonstrated that the minutes [median (IQR)] of D-NIV used significantly increased at the three time points (0–1 month, 3–4 months and 11–12 months) for patients with hypertension [310 (147.5–431) vs. 341 (89–450) vs. 378 (224.5–477.5), p = 0.003]; diabetes [296.5 (132.5–417.5) vs. 342.5 (94.5–438.5) vs. 382 (247.5–476.25), p = 0.002] and heart failure [293 (177–403) vs. 326 (123–398) vs. 365 (212–493), p = 0.04]. In conclusion, younger and comorbid schizophrenic patients have lower D-NIV compliance rates, and our data suggest that persistence with D-NIV over a year may improve overall use.

6 November 2020 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
NDNikesh Devani
Nikesh Devani
TATom Aslan
Tom Aslan
FLFiona Leske
Fiona Leske
SMStephanie K Mansell
Stephanie K Mansell
SMSarah Morgan
Sarah Morgan
SMSwapna Mandal
Swapna Mandal
Background Obstructive sleep apnoea (OSA) presents a major healthcare challenge with current UK data suggesting that only 22% of individuals have been diagnosed and treated. Promoting awareness and improving access to diagnostics are fundamental in addressing these missing cases and the recognised complications associated with untreated OSA. Diagnosis usually occurs in secondary care with data from our trust revealing long wait times to undertake tests, reach a diagnosis and start treatment. This places a considerable time and emotional burden on the patient and a financial and logistical burden on the hospital. Methods We introduced an integrated community-based pathway for the diagnosis of OSA. This comprised a monthly clinic run from within a local general practice (GP) supported by a ‘virtual multidisciplinary team’ run by the hospital specialist team. Prospective collection of process, outcome and patient satisfaction data was compared with traditional hospital-based pathway data collected retrospectively. Setting A central London teaching hospital and GPs within a local commissioning neighbourhood. Results Between January 2018 and February 2019, 70 were patients referred and managed along the community pathway. Compared with the hospital pathway, data demonstrated a significant reduction in the time taken: from referral to perform a sleep test (29 vs 181 days, p<0.0001), to make a diagnosis (40 vs 230 days, p<0.0001) and commence treatment (127 vs 267, p<0.0001). Patient satisfaction in the community pathway was higher across all domains (p<0.05), fewer hospital outpatient appointments were required and cost estimates suggested an overall saving of up to £290 could be achieved for each patient. Conclusion An integrated community-based pathway results in more timely diagnosis of OSA within a local setting while maintaining specialist input from the hospital team. It is favoured by patients and can reduce unnecessary appointments in secondary care.

27 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RARawan S. Abdulsadig
Rawan S. Abdulsadig
NDNikesh Devani
Nikesh Devani
SSSukhpreet Singh
Sukhpreet Singh
ZPZaibaa Patel
Zaibaa Patel
RPRenard Xaviero Adhi Pramono
Renard Xaviero Adhi Pramono
Esther Rodriguez-VillegasEsther Rodriguez-Villegas
Esther Rodriguez-Villegas
Objectives: Respiratory rate (RR) is a clinical measure of breathing frequency, a vital metric for clinical assessment. However, the recording and documentation of RR are considered to be extremely poor due to the limitations of the current approaches to measuring RR, including capnography and manual counting. We conducted a validation of the automatic RR measurement capability of AcuPebble RE100 (Acurable, London, UK) against a gold-standard capnography system and a type-III cardiorespiratory polygraphy system in two independent prospective and retrospective studies. Methods: The experiment for the prospective study was conducted at Imperial College London. Data from AcuPebble RE100 (Acurable, London, UK) and the reference capnography system (Capnostream™35, Medtronic, Minneapolis, MN, USA) were collected simultaneously from healthy volunteers. The data from a previously published study were used in the retrospective study, where the patients were recruited consecutively from a standard Obstructive Sleep Apnea (OSA) diagnostic pathway in a UK hospital. Overnight data during sleep were collected using the AcuPebble SA100 (Acurable, London, UK) sensor and a type-III cardiorespiratory polygraphy system (Embletta MPR Sleep System, Natus Medical, Pleasanton, CA, USA) at the patients’ homes. Data from 15 healthy volunteers were used in the prospective study. For the retrospective study, 150 consecutive patients had been referred for OSA diagnosis and successfully completed the study. Results: The RR output of AcuPebble RE100 (Acurable, London, UK) was compared against the reference device in terms of the Root Mean Squared Deviation (RMSD), mean error, and standard deviation (SD) of the difference between the paired measurements. In both the prospective and retrospective studies, the AcuPebble RE100 algorithms provided accurate RR measurements, well within the clinically relevant margin of error, typically used by FDA-approved respiratory rate monitoring devices, with the RMSD under three breaths per minute (BPM) and mean errors of 1.83 BPM and 1.4 BPM, respectively. Conclusions: The evaluation results provide evidence that AcuPebble RE100 (Acurable, London, UK) algorithms produce reliable results and are hence suitable for overnight monitoring of RR.